MetE: a promising protective antigen for tuberculosis vaccine development

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Tuberculosis (TB) remains a global health challenge.
• The current Bacillus Calmette-Guérin (BCG) vaccine offers inconsistent protection.
• Novel vaccine candidates are urgently needed to combat Mycobacterium tuberculosis (MTB).

Purpose of the Study:

• To identify and evaluate novel MTB antigens as potential TB vaccine candidates.
• To assess the protective efficacy of identified antigens in preclinical models.

Main Methods:

• Immunopeptidomics was used to identify unique mycobacterial antigens from BCG and MTB.
• An immunoinformatics approach prioritized antigens based on HLA allele coverage.
• Candidate antigens (hisD, metE, mmpL12) were tested as DNA vaccines and recombinant proteins in murine models.

Main Results:

• The antigen 'metE' demonstrated significant protective efficacy in vivo against MTB challenge.
• metE, formulated with AS01™ or AddaS03™ adjuvants, conferred protection compared to a control group.
• Different adjuvant formulations induced distinct immunogenic profiles, including cytokine and antibody responses.

Conclusions:

• The antigen 'metE' is a promising candidate for future tuberculosis vaccine development.
• Further research into metE-based vaccines is warranted to combat TB effectively.